Drug
Livmoniplimab clinical trials
Also written ABBV-151.
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
6 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Budigalimab (6) · Pembrolizumab (1) · Docetaxel (1) · Paclitaxel (1) · Gemcitabine (1)
Studies
Open first, then newest update. How each study uses livmoniplimab is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)TerminatedPhase 1AbbVieNCT06487559Written as Livmoniplimab
- Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2/3AbbVieNCT06236438Written as Livmoniplimab
- A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2/3AbbVieNCT06109272Written as Livmoniplimab
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2AbbVieNCT05822752Written as Livmoniplimab
- Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)Active, not recruitingPhase 2AbbVieNCT06632951Written as Livmoniplimab
- Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1AbbVieNCT03821935Written as Livmoniplimab
Codes
What other systems call livmoniplimab · ClinicalTrials.gg INT014780
- UNII (FDA) 42SH7JCD82LIVMONIPLIMABOne source FDA
- NCI Thesaurus C165684LivmoniplimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 42SH7JCD82 | LIVMONIPLIMAB | One source FDA |
| NCI Thesaurus | C165684 | Livmoniplimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.